^
    Back
    Association details:
    Biomarker:MECOM mutation + KDM6B mutation
    Cancer:Myelodysplastic Syndrome
    Drug:lenalidomide (TNFα inhibitor, IL-6 inhibitor, IL-12 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    New
    Source:
    ASH 2018
    Title:

    Genomic Biomarkers Predict Response/Resistance to Lenalidomide in Non-Del(5q) Myelodysplastic Syndromes Genomic Biomarkers Predict Response/Resistance to Lenalidomide in Non-Del(5q) Myelodysplastic Syndromes

    Excerpt:
    Of 139 pts treated with Len as monotherapy or in combination for at least 2 cycles included, 118 (85%) had MDS...Association rules identified the following combinations of genomic/cytogenetic abnormalities to predict response to Len in non-del(5q): (DDX41, NK) and (MECOM, KDM6A/KDM6B).
    DOI:
    10.1182/blood-2018-99-114681